A

Athenex Inc
F:2MT

Watchlist Manager
Athenex Inc
F:2MT
Watchlist
Price: 0.12 EUR Market Closed
Market Cap: 715.7m EUR

Relative Value

2MT price has not been updated for more than 6 years. This may indicate that the stock has been delisted.

There is not enough data to reliably calculate the relative value of 2MT.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

2MT Relative Value
Base Case
Not Available
A
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
vs Industry
Median 3Y
5.9
Median 5Y
6
Industry
7.2
Forward
8.1
vs History
vs Industry
Median 3Y
-6.4
Median 5Y
-6.3
Industry
23.2
Forward
-21.4
vs History
vs Industry
Median 3Y
-10.3
Median 5Y
-7.6
Industry
19.3
vs History
vs Industry
Median 3Y
-6.9
Median 5Y
-6.9
Industry
22.5
vs History
vs Industry
Median 3Y
-118.6
Median 5Y
3.7
Industry
2.7
vs History
vs Industry
Median 3Y
6.3
Median 5Y
6.3
Industry
7.5
Forward
8.6
vs History
vs Industry
Median 3Y
25
Median 5Y
24.8
Industry
9.4
vs History
vs Industry
Median 3Y
-9.3
Median 5Y
-8.4
Industry
4.6
vs History
vs Industry
Median 3Y
-9.1
Median 5Y
-8.1
Industry
4.5
vs History
vs Industry
Median 3Y
-11
Median 5Y
-8.3
Industry
4.9
vs History
vs Industry
Median 3Y
-10.7
Median 5Y
-8.1
Industry
3.7
vs History
vs Industry
Median 3Y
6
Median 5Y
5.2
Industry
4.9

Multiples Across Competitors

2MT Competitors Multiples
Athenex Inc Competitors

Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Athenex Inc
F:2MT
715.7m EUR 6.3 -6.9 -10 -9.7
FR
Pharnext SCA
OTC:PNEXF
6T USD 34 202 723.3 -162 560.5 -197 400.3 -195 147.7
US
Abbvie Inc
NYSE:ABBV
337.5B USD 5.9 81.2 15.4 22.8
US
Amgen Inc
NASDAQ:AMGN
158.7B USD 4.7 26.8 14.4 23.7
US
Gilead Sciences Inc
NASDAQ:GILD
136.9B USD 4.8 23 10 13.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
117B USD 10.5 -118.3 25.2 26.4
US
Epizyme Inc
F:EPE
94.1B EUR 2 059.8 -525.6 -572.3 -557.1
AU
CSL Ltd
ASX:CSL
115.7B AUD 4.9 27.3 16.9 21.1
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
57.3B USD 4.1 12.7 11.3 12.7
US
Seagen Inc
F:SGT
39.3B EUR 19.8 -60.8 -65.6 -59.2
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
40.1B USD 17.1 -148.8 -666.4 -333.9
P/S Multiple
Revenue Growth P/S to Growth
US
A
Athenex Inc
F:2MT
Average P/S: 3 109 532.8
6.3
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
34 202 723.3
N/A N/A
US
Abbvie Inc
NYSE:ABBV
5.9
8%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.7
4%
1.2
US
Gilead Sciences Inc
NASDAQ:GILD
4.8
3%
1.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
10.5
10%
1.1
US
E
Epizyme Inc
F:EPE
2 059.8
N/A N/A
AU
CSL Ltd
ASX:CSL
4.9
7%
0.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
4.1
4%
1
US
S
Seagen Inc
F:SGT
19.8
30%
0.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
17.1
29%
0.6
P/E Multiple
Earnings Growth PEG
US
A
Athenex Inc
F:2MT
Average P/E: 34.2
Negative Multiple: -6.9
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -162 560.5 N/A N/A
US
Abbvie Inc
NYSE:ABBV
81.2
88%
0.9
US
Amgen Inc
NASDAQ:AMGN
26.8
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
23
188%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -118.3 N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -525.6 N/A N/A
AU
CSL Ltd
ASX:CSL
27.3
16%
1.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
12.7
7%
1.8
US
S
Seagen Inc
F:SGT
Negative Multiple: -60.8 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -148.8 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
A
Athenex Inc
F:2MT
Average EV/EBITDA: 15.5
Negative Multiple: -10
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -197 400.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.4
13%
1.2
US
Amgen Inc
NASDAQ:AMGN
14.4
17%
0.8
US
Gilead Sciences Inc
NASDAQ:GILD
10
6%
1.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.2
17%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -572.3 N/A N/A
AU
CSL Ltd
ASX:CSL
16.9
11%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
11.3
11%
1
US
S
Seagen Inc
F:SGT
Negative Multiple: -65.6 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -666.4 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
A
Athenex Inc
F:2MT
Average EV/EBIT: 20.1
Negative Multiple: -9.7
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -195 147.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
22.8
29%
0.8
US
Amgen Inc
NASDAQ:AMGN
23.7
32%
0.7
US
Gilead Sciences Inc
NASDAQ:GILD
13.8
11%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26.4
17%
1.6
US
E
Epizyme Inc
F:EPE
Negative Multiple: -557.1 N/A N/A
AU
CSL Ltd
ASX:CSL
21.1
14%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
12.7
11%
1.2
US
S
Seagen Inc
F:SGT
Negative Multiple: -59.2 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -333.9 N/A N/A